Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia.
D001132:Arm / Q000098:blood supply*; D002110:Caffeine / Q000009:adverse effects / Q000627:therapeutic use; D004878:Ergotamine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005292:Ferricyanides / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D007511:Ischemia / Q000139:chemically induced / Q000188:drug therapy*; D007866:Leg / Q000098:blood supply*; D008722:Methods; D008875:Middle Aged; D009569:Nitric Oxide / Q000008:administration & dosage / Q000627:therapeutic use; D013488:Suppositories / Q000009:adverse effects / Q000627:therapeutic use; D013644:Tartrates / Q000009:adverse effects / Q000627:therapeutic use; D014653:Vascular Headaches / Q000188:drug therapy; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D005292:Ferricyanides; D013488:Suppositories; D013644:Tartrates; D014665:Vasodilator Agents; D009569:Nitric Oxide; D002110:Caffeine; D004878:Ergotamine